戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tion led to the identification of the potent antitubercular 2-thio-substituted quinazolinone 26.
2 ne destabilizing and metabolic mechanisms of antitubercular action for MAD1-RI, and in doing so ident
3  4- and 5-nitroimidazoles and explored their antitubercular activities.
4 (IC(50) = 11.2 muM) and a promising in vitro antitubercular activity (MIC(99) = 32 muM against M. bov
5 ied, CyC 17 exhibited the best extracellular antitubercular activity (MIC50 = 500 nM).
6 azolopyridine ureas as a novel scaffold with antitubercular activity acting through inhibition of DNA
7  all other phytocompounds showing remarkable antitubercular activity against the Mtb H37Ra strain.
8 nt MbtI inhibitors demonstrating significant antitubercular activity and a favorable safety profile w
9 nt phytocompound o-vanillin, which possesses antitubercular activity and can potentially be used as a
10 esulted in compounds with moderate to potent antitubercular activity and improved physicochemical pro
11               New prospective scaffolds with antitubercular activity derived from homo-piperazine, ph
12  Mycobacterium tuberculosis RNAP but lowered antitubercular activity in cell culture under both aerob
13 favorable therapeutic index and enhanced the antitubercular activity of the first-line drugs isoniazi
14 A inhibitors disclosed here display in vitro antitubercular activity superior to most current first l
15 ructure-activity relationships lining up the antitubercular activity were exploited for the rational
16 derivative 26 exhibited exceptionally potent antitubercular activity with an MIC99 under iron-deficie
17 assessed for biochemical potency, whole-cell antitubercular activity, and in vivo pharmacokinetic par
18 al role for both meta-nitro substituents for antitubercular activity, while the introduction of polar
19 ing a nitroimidazopyran nucleus that possess antitubercular activity.
20 lation may be an integral component of PZA's antitubercular activity.
21 s (Mtb) in order to identify novel hits with antitubercular activity.
22 -phenoxypropyl)-1H-benzo[d]imidazole for its antitubercular activity.
23 xhibits exceptionally potent biochemical and antitubercular activity.
24 1) as the primary target responsible for the antitubercular activity.
25 mal inhibition and excellent narrow-spectrum antitubercular activity.
26 of mycobactin biosynthesis, exhibited potent antitubercular activity.
27 soniazid-NADH adduct that ultimately confers antitubercular activity.
28 of basic cyclic peptides that exhibit potent antitubercular activity.
29 ine action where chlorpromazine, a promising antitubercular agent and key medicine used to treat psyc
30                                          The antitubercular agent isoniazid can be activated by Mycob
31                                              Antitubercular agent levesquamide is a new polyketide-no
32 icals found with KatG, while the less potent antitubercular agent nicotinic acid hydrazide produced t
33  The potential of compound 5f as a promising antitubercular agent was further strengthened by in sili
34 -carboxamide analogue, 3, as a highly potent antitubercular agent, and the subsequent chemical modifi
35       In this work, rifampicin, a first-line antitubercular agent, was encapsulated into biocompatibl
36 y, alone and in combination with second-line antitubercular agents (moxifloxacin or bedaquiline), the
37            This makes the discovery of novel antitubercular agents a cogent priority.
38 is (Mtb) to look for inducible expression of antitubercular agents and identified 5 fungi that produc
39  that can be exploited for the design of new antitubercular agents and/or diagnostic tools.
40 alues lower than those of the most prominent antitubercular agents currently in use.
41     The urgent need for safer and innovative antitubercular agents remains a priority for the scienti
42        Application of MycoBCP to a series of antitubercular agents successfully identified known MOAs
43 derscores the urgent need for new classes of antitubercular agents targeting novel pathways.
44             Pretomanid and delamanid are new antitubercular agents that have progressed through the d
45  (Sal-AMS) is a prototype for a new class of antitubercular agents that inhibit the aryl acid adenyla
46 red the discovery of a novel class of potent antitubercular agents that unexpectedly possessed notabl
47 s and identified 5 fungi that produced cidal antitubercular agents upon exposure to live Mtb.
48 elevant for increasing the concentrations of antitubercular agents within the infected site and reduc
49 re a promising class of potent and selective antitubercular agents, if the metabolic liability can be
50 rotein and a validated target to develop new antitubercular agents, particularly for the treatment of
51 rotein and a validated target to develop new antitubercular agents, particularly for the treatment of
52 ntify small molecule inhibitors as potential antitubercular agents.
53 igase) is a key target for the design of new antitubercular agents.
54 tency greater than that of many conventional antitubercular agents.
55 suggesting that it can be developed as a new antitubercular aimed at the acute infection.
56 opyrazinone bicyclic subclass with promising antitubercular and antiparasitic activity, prompting add
57  recent advances in the field of anticancer, antitubercular and antiparasitic agents containing nitro
58                                     Improved antitubercular and antitrypanosomal activity was observe
59                Lesions responded to combined antitubercular and steroid therapy, usually spared fovea
60                            Mycobacidin is an antitubercular antibiotic structurally composed of a sul
61 cal basis for the effectiveness of the first antitubercular B-lactams.
62 vely explored for their potential use as new antituberculars based on their excellent bactericidal pr
63 ells as a putative mechanism of the observed antitubercular benefits in the absence of chemotherapy.
64 unction with isoniazid, but removed from the antitubercular chemotherapeutic arsenal due to toxic sid
65 ty, such as the JmjC inhibitor ML324 and the antitubercular clinical candidate SQ109.
66                      Many diverse classes of antitubercular compounds have been identified with activ
67 ived cholesterol to develop a novel class of antitubercular compounds that target Mtb CYP125 and CYP1
68 tivity, 87% precision) with a test set of 75 antitubercular compounds with known MOA previously repor
69                       From 98 additional GSK antitubercular compounds with unknown MOA, we predict 60
70 f the CYP121 enzyme, in the search for novel antitubercular compounds.
71  biosynthesis, DNA repair, and activation of antitubercular compounds.
72 afish larvae for in vivo characterization of antitubercular drug activity and tolerance.
73 netics (PK) often represents a challenge for antitubercular drug development.
74   MbtA is a validated therapeutic target for antitubercular drug development.
75 sect with its metabolism and be exploited in antitubercular drug discovery.
76 dy tuberculosis pathogenesis, as well as for antitubercular drug discovery.
77 tuberculosis, is the target of the frontline antitubercular drug isoniazid (INH).
78                                The preferred antitubercular drug isoniazid specifically targets a lon
79 obacterium tuberculosis and a target for the antitubercular drug isoniazid.
80  clearance in mice during treatment with the antitubercular drug isoniazid.
81 sis is responsible for the activation of the antitubercular drug isonicotinic acid hydrazide (INH) an
82 at M. tuberculosis transports the first-line antitubercular drug rifampicin through a proton gradient
83 s is inhibited by isoniazid, a key frontline antitubercular drug that is inactivated by mycobacterial
84                              Bedaquiline, an antitubercular drug that targets ATP-synthase, is a key
85 s the efficacy of ethionamide, a second-line antitubercular drug used to combat multidrug-resistant M
86                 Isoniazid (INH), a frontline antitubercular drug, inhibits InhA, the enoyl reductase
87 erium marinum to thiacetazone, a second line antitubercular drug, is associated with a severe decreas
88 ponsible for activation of the commonly used antitubercular drug, isoniazid (INH).
89 e for increased resistance to the front-line antitubercular drug, isoniazid, by acetylating and hence
90 losis, is important in the activation of the antitubercular drug, isoniazid.
91  study used Fischer 344 rats primed with the antitubercular drug, rifampicin, plus phenobarbitone, an
92 ates Pks13 as an attractive novel target for antitubercular drugs and supports development of alterna
93 e originally been designed as hybrids of the antitubercular drugs BM212 (1) and SQ109 (2), which show
94            Rationale: Standardized dosing of antitubercular drugs contributes to a substantial incide
95                                     Standard antitubercular drugs exhibit various limitations like to
96 g pocket of Eis is a potential target of new antitubercular drugs expected to overcome aminoglycoside
97 acogenomic assays that predict metabolism of antitubercular drugs have been lacking.
98      One challenge to the development of new antitubercular drugs is the existence of multiple virule
99                              We examined the antitubercular drugs isoniazid, rifampicin, and moxiflox
100            Rationale: Standardized dosing of antitubercular drugs leads to variable plasma drug level
101  tuberculosis compared to the two first-line antitubercular drugs rifampicin and isoniazid.
102 ween these two components was provided using antitubercular drugs such as ethambutol or isoniazid kno
103 nt enzymes, which hampers the development of antitubercular drugs targeting this pathway.
104 osis highlights the need for identifying new antitubercular drugs that can treat these infections.
105                                 However, new antitubercular drugs with new mechanisms of action have
106 ly) TB; hence the quest for highly effective antitubercular drugs with novel modes of action is imper
107 ssociate binary resistance phenotypes for 15 antitubercular drugs with variants extracted from candid
108 ) has been shown to increase the efficacy of antitubercular drugs, and fusing macrophage-inflammatory
109 ation issues, including interactions between antitubercular drugs, antiretroviral drugs, and medicine
110       The mechanisms of action of the unique antitubercular drugs, including isoniazid, ethambutol, a
111                       In contrast to current antitubercular drugs, nitroimidazopyrans exhibited bacte
112 Ps in five genes affecting the metabolism of antitubercular drugs.
113 rovide targets for development of innovative antitubercular drugs.
114  be leveraged to develop new, more effective antitubercular drugs.
115 the development of a novel chemical class of antitubercular drugs.
116 otential target for the development of novel antitubercular drugs.
117 AGP is also regarded as a target for several antitubercular drugs.
118 otential to be developed into a new class of antitubercular drugs.
119 otential target to develop antibacterial and antitubercular drugs.
120 is (Mtb), as adjunctive treatment given with antitubercular drugs.
121 um tuberculosis and is the target of several antitubercular drugs.
122 rculosis (M. tb) emphasizes the need for new antitubercular drugs.
123 M/LM balance might represent targets for new antitubercular drugs.
124  the oxidative activation of other thioamide antitubercular drugs.
125 ation of an aromatic nitro group to exert an antitubercular effect.
126 ne peptides showed in vivo antibacterial and antitubercular efficacies against Escherichia coli ATCC
127                                          The antitubercular efficacy of spectinamides demonstrates th
128 ion of the 3,5-dinitrophenyl fragment in the antitubercular efficiency.
129 a novel yet unknown mode of action for these antitubercular hits.
130 s an enzymatic defense against an element of antitubercular immunity.
131 ability to evolve acquired resistance to all antituberculars in clinical use.
132                            Activation of the antitubercular isoniazid (INH) by the Mycobacterium tube
133 y space if we are to generate novel improved antitubercular leads.
134 s of structure 1, previously assigned to the antitubercular marine natural product pseudopteroxazole,
135 acene-6,11,13-trione (1), proposed to be the antitubercular natural product eucapsitrione, has been s
136              A formal total synthesis of the antitubercular natural product was accomplished.
137 lead compounds were identified with improved antitubercular potencies (MIC < 1 muM) and in vitro ADME
138 wed with good enzymatic potency but with low antitubercular potency.
139  by in vitro and in vivo evaluation of their antitubercular potential against Mtb.
140 tive stress management and activation of the antitubercular pro-drug isoniazid.
141                          Key to their potent antitubercular properties was their structural modificat
142 gh purine metabolism represents an essential antitubercular target, concerns about host nucleobase re
143 rculosis emphasize the necessity to find new antitubercular targets and drugs.
144                          Here we describe an antitubercular that targets de novo fatty acid synthesis
145            Resistance against currently used antitubercular therapeutics increasingly undermines effo
146 G) vaccine, and to uncover targets for novel antitubercular therapeutics.
147 d as a possible target for the design of new antitubercular therapeutics.
148 may result in persistent symptoms even after antitubercular therapy (ATT) and may require surgical in
149 due to inflammatory lesions, despite optimal antitubercular therapy (ATT) and steroids.
150 y (COTS) calculator in guiding initiation of antitubercular therapy (ATT) in patients with clinically
151 nce of international agreement on the use of antitubercular therapy (ATT) in patients with TBU contri
152 guide physicians regarding the initiation of antitubercular therapy (ATT) in patients with TBU.
153 berculosis and its effect on the response to antitubercular therapy (ATT) is incompletely understood.
154 p from initiation of treatment that included antitubercular therapy (ATT) with oral corticosteroids (
155 veitis and the associations with response to antitubercular therapy (ATT).
156 y virus (HIV)-infected patients on RIF-based antitubercular therapy in the French National Agency for
157 s in well-validated biosynthetic pathways in antitubercular therapy is a powerful strategy that remov
158  specific efflux pump inhibitors to standard antitubercular therapy should shorten the duration of cu
159                                              Antitubercular therapy significantly reduced recurrences
160 protein constitutes an attractive target for antitubercular therapy, also considering the absence of
161 arditis in endemic areas and is treated with antitubercular therapy.
162  confirmed rifampin monoresistance following antitubercular therapy.
163 ts pave the way for the development of novel antituberculars through the rational design of improved
164 lu-Natal, South Africa, who received minimal antitubercular treatment and most of whom were HIV serop
165 lead candidate for further development as an antitubercular vaccine.

 
Page Top